Works by Scemama, Michel

Results: 6
    1

    First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection

    Published in:
    British Journal of Clinical Pharmacology, 2021, v. 87, n. 2, p. 598, doi. 10.1111/bcp.14422
    By:
    • Bergougnan, Luc;
    • Armani, Sara;
    • Golor, Georg;
    • Tardat, Agnes;
    • Vitse, Olivier;
    • Hurbin, Fabrice;
    • Scemama, Michel;
    • Poitiers, Franck;
    • Radzik, David;
    • Gaudin, Christophe;
    • Hovsepian, Lionel;
    • Muslin, Anthony J.;
    • Kirkesseli, Stephane;
    • Deutsch, Paul;
    • Parkar, Ashfaq A.
    Publication type:
    Article
    2
    3
    4
    5

    Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.

    Published in:
    European Heart Journal, 2023, v. 44, n. 16, p. 1408, doi. 10.1093/eurheartj/ehad144
    By:
    • Schwartz, Gregory G;
    • Szarek, Michael;
    • Bhatt, Deepak L;
    • Bittner, Vera A;
    • Bujas-Bobanovic, Maja;
    • Diaz, Rafael;
    • Fazio, Sergio;
    • Fras, Zlatko;
    • Goodman, Shaun G;
    • Harrington, Robert A;
    • Jukema, J Wouter;
    • Manvelian, Garen;
    • Pordy, Robert;
    • Ray, Kausik K;
    • Scemama, Michel;
    • White, Harvey D;
    • Steg, Ph Gabriel;
    • Investigators, for the ODYSSEY OUTCOMES
    Publication type:
    Article
    6